Concepts (136)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Endometrial Neoplasms | 9 | 2021 | 193 | 1.890 |
Why?
|
| Genital Neoplasms, Female | 5 | 2021 | 107 | 1.870 |
Why?
|
| Oncologists | 3 | 2021 | 35 | 1.710 |
Why?
|
| Neoplasm Recurrence, Local | 7 | 2021 | 1307 | 1.000 |
Why?
|
| Ovarian Neoplasms | 5 | 2022 | 742 | 0.960 |
Why?
|
| Intestinal Obstruction | 2 | 2021 | 88 | 0.930 |
Why?
|
| Drug Costs | 1 | 2021 | 62 | 0.760 |
Why?
|
| Cost-Benefit Analysis | 1 | 2021 | 451 | 0.670 |
Why?
|
| Telemedicine | 1 | 2021 | 169 | 0.660 |
Why?
|
| Adenocarcinoma | 3 | 2015 | 1168 | 0.490 |
Why?
|
| Pandemics | 5 | 2022 | 739 | 0.460 |
Why?
|
| Carcinosarcoma | 1 | 2011 | 20 | 0.400 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2021 | 2436 | 0.390 |
Why?
|
| Uterine Neoplasms | 2 | 2019 | 226 | 0.360 |
Why?
|
| Female | 24 | 2022 | 44489 | 0.330 |
Why?
|
| Palliative Care | 2 | 2021 | 257 | 0.330 |
Why?
|
| Cross-Sectional Studies | 5 | 2022 | 1619 | 0.270 |
Why?
|
| Humans | 27 | 2022 | 86526 | 0.270 |
Why?
|
| Carcinoma, Papillary | 1 | 2007 | 158 | 0.270 |
Why?
|
| Colorectal Neoplasms | 2 | 2021 | 938 | 0.230 |
Why?
|
| Quality of Life | 2 | 2022 | 1583 | 0.230 |
Why?
|
| Mental Health | 2 | 2021 | 162 | 0.230 |
Why?
|
| Aged | 13 | 2022 | 18398 | 0.210 |
Why?
|
| Socioeconomic Factors | 2 | 2021 | 567 | 0.210 |
Why?
|
| Morbidity | 1 | 2022 | 148 | 0.200 |
Why?
|
| Decision Trees | 1 | 2021 | 63 | 0.200 |
Why?
|
| Microsatellite Instability | 1 | 2021 | 43 | 0.200 |
Why?
|
| Alphapapillomavirus | 1 | 2021 | 45 | 0.200 |
Why?
|
| Hysterectomy | 3 | 2019 | 146 | 0.200 |
Why?
|
| Markov Chains | 1 | 2021 | 125 | 0.200 |
Why?
|
| Phenylurea Compounds | 1 | 2021 | 113 | 0.190 |
Why?
|
| Papillomavirus Vaccines | 1 | 2021 | 58 | 0.190 |
Why?
|
| Quality-Adjusted Life Years | 1 | 2021 | 138 | 0.190 |
Why?
|
| Quinolines | 1 | 2021 | 95 | 0.190 |
Why?
|
| Depression | 2 | 2021 | 472 | 0.190 |
Why?
|
| Hyperthermia, Induced | 1 | 2021 | 72 | 0.190 |
Why?
|
| Chicago | 3 | 2020 | 1379 | 0.190 |
Why?
|
| Carboplatin | 1 | 2021 | 286 | 0.190 |
Why?
|
| Peritoneal Neoplasms | 1 | 2021 | 176 | 0.180 |
Why?
|
| Referral and Consultation | 2 | 2020 | 326 | 0.180 |
Why?
|
| Paclitaxel | 1 | 2021 | 460 | 0.170 |
Why?
|
| Neoadjuvant Therapy | 1 | 2021 | 317 | 0.170 |
Why?
|
| Antibodies, Monoclonal, Humanized | 2 | 2021 | 930 | 0.160 |
Why?
|
| Longitudinal Studies | 1 | 2022 | 1019 | 0.160 |
Why?
|
| Health Equity | 1 | 2020 | 77 | 0.160 |
Why?
|
| Papillomavirus Infections | 1 | 2021 | 239 | 0.160 |
Why?
|
| Aged, 80 and over | 9 | 2021 | 6501 | 0.160 |
Why?
|
| Health Resources | 1 | 2018 | 76 | 0.160 |
Why?
|
| Stress, Psychological | 1 | 2021 | 313 | 0.160 |
Why?
|
| Neoplasm Staging | 2 | 2021 | 1937 | 0.160 |
Why?
|
| Communication | 1 | 2021 | 440 | 0.150 |
Why?
|
| Self Care | 1 | 2018 | 164 | 0.150 |
Why?
|
| Hyperlipidemias | 1 | 2016 | 95 | 0.140 |
Why?
|
| Carcinoma, Endometrioid | 1 | 2016 | 43 | 0.140 |
Why?
|
| Middle Aged | 13 | 2021 | 25013 | 0.140 |
Why?
|
| Physician-Patient Relations | 1 | 2021 | 610 | 0.140 |
Why?
|
| Healthcare Disparities | 1 | 2020 | 370 | 0.130 |
Why?
|
| Corneal Injuries | 1 | 2015 | 10 | 0.130 |
Why?
|
| Radiotherapy, Adjuvant | 2 | 2019 | 291 | 0.130 |
Why?
|
| Endometrial Hyperplasia | 1 | 2015 | 8 | 0.130 |
Why?
|
| Venous Thromboembolism | 1 | 2017 | 151 | 0.130 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 316 | 0.130 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 301 | 0.130 |
Why?
|
| Chemotherapy, Adjuvant | 2 | 2019 | 468 | 0.130 |
Why?
|
| Retrospective Studies | 8 | 2021 | 8464 | 0.120 |
Why?
|
| Basic Helix-Loop-Helix Transcription Factors | 1 | 2015 | 165 | 0.120 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2016 | 378 | 0.110 |
Why?
|
| Neoplasm Metastasis | 2 | 2019 | 1056 | 0.110 |
Why?
|
| Sexual Behavior | 1 | 2015 | 302 | 0.100 |
Why?
|
| Obesity | 1 | 2018 | 963 | 0.100 |
Why?
|
| Adult | 10 | 2021 | 25627 | 0.100 |
Why?
|
| Prostatectomy | 1 | 2015 | 471 | 0.100 |
Why?
|
| Pyrazoles | 1 | 2012 | 153 | 0.100 |
Why?
|
| Prognosis | 3 | 2021 | 3673 | 0.100 |
Why?
|
| Cytoreduction Surgical Procedures | 2 | 2021 | 72 | 0.090 |
Why?
|
| Chemoradiotherapy | 1 | 2012 | 301 | 0.090 |
Why?
|
| Pyrimidines | 1 | 2012 | 370 | 0.090 |
Why?
|
| Uterine Cervical Neoplasms | 1 | 2012 | 275 | 0.090 |
Why?
|
| Anxiety | 2 | 2021 | 287 | 0.090 |
Why?
|
| Molecular Targeted Therapy | 1 | 2011 | 266 | 0.090 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2012 | 592 | 0.080 |
Why?
|
| Multivariate Analysis | 2 | 2012 | 999 | 0.080 |
Why?
|
| Postoperative Complications | 2 | 2017 | 2205 | 0.080 |
Why?
|
| Young Adult | 5 | 2021 | 5971 | 0.080 |
Why?
|
| Biomarkers, Tumor | 1 | 2015 | 1461 | 0.070 |
Why?
|
| Disease-Free Survival | 3 | 2015 | 1204 | 0.070 |
Why?
|
| Neoplasms | 1 | 2021 | 2895 | 0.070 |
Why?
|
| Antineoplastic Agents | 2 | 2019 | 2357 | 0.070 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2012 | 1075 | 0.070 |
Why?
|
| Adolescent | 3 | 2021 | 8976 | 0.060 |
Why?
|
| Proportional Hazards Models | 1 | 2007 | 857 | 0.060 |
Why?
|
| United States | 3 | 2021 | 6662 | 0.060 |
Why?
|
| Incidence | 2 | 2021 | 1576 | 0.060 |
Why?
|
| Risk Factors | 3 | 2021 | 5413 | 0.060 |
Why?
|
| Survival Analysis | 1 | 2007 | 1537 | 0.060 |
Why?
|
| Cohort Studies | 2 | 2021 | 2765 | 0.050 |
Why?
|
| Age Factors | 1 | 2007 | 1849 | 0.050 |
Why?
|
| Rural Health Services | 1 | 2021 | 13 | 0.050 |
Why?
|
| Treatment Outcome | 3 | 2021 | 7981 | 0.050 |
Why?
|
| Rural Population | 1 | 2021 | 136 | 0.050 |
Why?
|
| Geography | 1 | 2021 | 223 | 0.050 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2012 | 860 | 0.050 |
Why?
|
| Social Class | 1 | 2020 | 127 | 0.040 |
Why?
|
| Survivors | 1 | 2021 | 226 | 0.040 |
Why?
|
| Bias | 1 | 2020 | 127 | 0.040 |
Why?
|
| Vaccination | 1 | 2021 | 254 | 0.040 |
Why?
|
| Sentinel Lymph Node | 1 | 2019 | 13 | 0.040 |
Why?
|
| Lymph Node Excision | 1 | 2019 | 213 | 0.040 |
Why?
|
| Urban Population | 1 | 2018 | 213 | 0.040 |
Why?
|
| Poverty | 1 | 2018 | 173 | 0.040 |
Why?
|
| Cancer Survivors | 1 | 2018 | 85 | 0.040 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2021 | 508 | 0.040 |
Why?
|
| Endometrium | 1 | 2015 | 48 | 0.030 |
Why?
|
| Ki-67 Antigen | 1 | 2015 | 64 | 0.030 |
Why?
|
| Sexuality | 1 | 2015 | 40 | 0.030 |
Why?
|
| Receptors, Progesterone | 1 | 2015 | 167 | 0.030 |
Why?
|
| Population Surveillance | 1 | 2015 | 219 | 0.030 |
Why?
|
| Neoplasm Grading | 1 | 2015 | 357 | 0.030 |
Why?
|
| Self Report | 1 | 2015 | 288 | 0.030 |
Why?
|
| Receptors, Estrogen | 1 | 2015 | 384 | 0.030 |
Why?
|
| Robotic Surgical Procedures | 1 | 2017 | 267 | 0.030 |
Why?
|
| Robotics | 1 | 2015 | 267 | 0.030 |
Why?
|
| Radiation Dosage | 1 | 2012 | 227 | 0.030 |
Why?
|
| Brachytherapy | 1 | 2012 | 119 | 0.030 |
Why?
|
| Logistic Models | 1 | 2015 | 1185 | 0.020 |
Why?
|
| Administration, Oral | 1 | 2012 | 684 | 0.020 |
Why?
|
| Diagnosis, Differential | 1 | 2015 | 1564 | 0.020 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2019 | 2269 | 0.020 |
Why?
|
| Case-Control Studies | 1 | 2015 | 1803 | 0.020 |
Why?
|
| Neovascularization, Pathologic | 1 | 2012 | 353 | 0.020 |
Why?
|
| Child | 1 | 2021 | 6921 | 0.020 |
Why?
|
| Cell Proliferation | 1 | 2015 | 1578 | 0.020 |
Why?
|
| Laparoscopy | 1 | 2015 | 754 | 0.020 |
Why?
|
| Prostatic Neoplasms | 1 | 2015 | 1719 | 0.010 |
Why?
|
| Time Factors | 1 | 2012 | 5209 | 0.010 |
Why?
|
| Male | 1 | 2015 | 40944 | 0.010 |
Why?
|